查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2021685

寵物藥品市場預測至2034年－按產品類型、目標動物、給藥途徑、通路、應用和地區分類的全球分析

Pet Pharmaceuticals Market Forecasts to 2034 - Global Analysis By Product Type, Animal Type, Route of Administration, Distribution Channel, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 預測，全球寵物藥品市場預計到 2026 年將達到 180 億美元，並在預測期內以 8.5% 的複合年成長率成長，到 2034 年將達到 350 億美元。

寵物藥品是指用於預防、診斷和治療伴侶動物疾病的藥物，包括疫苗、感染疾病物、驅蟲藥、止痛藥和特殊療法。寵物飼養量的增加、寵物醫療保健支出的成長以及獸醫學的進步是推動該市場發展的因素。監管確保了藥物的安全性和有效性。人們對預防醫學和慢性病管理的日益重視，正在擴大對藥物解決方案的需求，使該領域成為更廣泛的動物保健行業的重要組成部分。

寵物飼養量和醫療保健支出增加

隨著寵物在世界各地的家庭中日益被視為家庭成員，對獸醫服務的需求也隨之成長。人們對預防保健和維持健康意識的提高，促進了藥品供應。各國政府和非政府組織正在推廣疫苗接種和寄生蟲防治項目，並提高了市場認知度。可支配收入的增加，使飼主能夠為寵物投資高品質的醫療保健方案。製藥公司正在拓展產品線，以滿足從伴侶動物到牲畜等各類寵物的多樣化需求。

監管核准的複雜性

寵物藥品必須經過嚴格的測試和認證，以確保其安全性和有效性。這個過程會增加成本，並可能延遲產品上市，尤其對於中小企業而言更是如此。法規結構的區域差異進一步增加了全球製造商面臨的複雜性。合規要求往往會限制創新並減緩商業化進程。企業面臨著如何在快速上市和嚴格的核准標準之間取得平衡的挑戰。隨著監管力道的加大，監管的複雜性將繼續限制寵物藥品產業的成長速度。

拓展醫療保健解決方案

疫苗、營養補充品和驅蟲藥等預防性產品在寵物飼主中越來越受歡迎。人們對長期健康益處的認知不斷提高，推動了預防保健的需求。各國政府都在支持預防性項目，以降低伴侶動物和牲畜的疾病發生率。製藥公司也加大研發投入，開發先進的預防性解決方案。與獸醫診所和寵物護理機構的合作，也促進了這些產品的普及。

嚴格的監理合規要求

世界各國政府對寵物藥品的生產、標籤和分銷都制定了嚴格的標準。違反這些標準可能導致產品召回、罰款和聲譽損害。與大型企業相比，中小企業往往難以滿足這些要求。區域監管的變化也為長期規劃帶來了不確定性。合規成本會增加營運負擔並降低盈利。未能確保合規性會使公司面臨失去市場佔有率和在寵物保健行業信譽的風險。

新冠疫情的影響：

新冠疫情對寵物藥品市場產生了複雜的影響。初期，供應鏈中斷減緩了動物用藥品的生產和分銷。然而，疫情封鎖期間寵物飼養量的增加提振了對寵物保健產品的需求。飼主尋求預防和健康維護方案，以確保寵物在疫情期間的安全。遠端醫療和線上零售平台成為藥品分銷的重要管道。世界各國政府將動物健康納入更廣泛的公共衛生措施中，並予以優先考慮。總而言之，新冠疫情改變了消費者的行為，同時也凸顯了寵物醫療保健產業韌性和適應性的重要性。

在預測期內，驅蟲藥市場預計將佔據最大的市場佔有率。

由於驅蟲藥在預防保健中的廣泛應用，預計在預測期內，驅蟲藥將佔據最大的市場佔有率。驅蟲藥能夠保護寵物免受跳蚤、蜱蟲和其他寄生蟲的侵害，確保它們的長期健康和安全。配方方面的持續創新正在提高其有效性和便利性。各國政府正透過宣傳宣傳活動和補助來支持寄生蟲控制計畫。獸醫診所也擴大將驅蟲藥作為日常護理的一部分。零售商正在擴大產品範圍，以滿足市場對這些產品的持續需求。

在預測期內，線上零售領域預計將呈現最高的複合年成長率。

在預測期內，由於消費者對更便利的購物體驗的需求不斷成長，預計線上零售領域將呈現最高的成長率。寵物飼主擴大透過電商平台購買藥品。線上通路提供更廣泛的產品選擇、更具競爭力的價格以及送貨上門服務。各國政府正透過基礎建設和政策框架支持數位零售的發展。製藥公司與線上平台的合作正在提升品牌知名度並促進銷售。數位行銷宣傳活動正在增強消費者參與度和品牌忠誠度。

市佔率最大的地區：

在預測期內，由於強勁的消費者需求和先進的獸醫基礎設施，北美預計將佔據最大的市場佔有率。美國在寵物醫療保健創新方面處於領先地位，並擁有種類繁多的藥品。政府支持的動物健康計畫確保了對預防和治療方案的穩定需求。知名品牌和零售商正在推動寵物藥品的商業化。對高級產品和有機產品日益成長的需求正在促使產品系列進行重組。投資者對以永續性為重點的項目的信心進一步推動了產品的普及。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於快速的都市化和不斷成長的可支配收入。中國、印度和日本等國家對寵物保健產品的需求強勁。政府主導的促進動物健康和福利的措施正在推動寵物保健產品的普及。本土Start-Ups正憑藉經濟高效且創新的解決方案進入市場，這些方案均針對當地需求量身定做。電子商務和現代獸醫服務的擴張進一步推動了市場成長。新興市場消費者對預防性醫療保健意識的提高正在改變他們的消費偏好。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對主要企業進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要企業市佔率分析
  • 產品基準評效和效能比較

第5章 全球寵物藥品市場：依產品類型分類

  • 感染疾病物
  • 抗發炎藥
  • 殺蟲劑
  • 疫苗
  • 疼痛管理藥物
  • 其他產品類型

第6章 全球寵物藥品市場：依動物類型分類

  • 狗
  • 貓
  • 馬
  • 鳥
  • 其他動物類型

第7章：全球寵物藥品市場：依給藥途徑分類

  • 口服
  • 注射藥物
  • 外用
  • 其他給藥途徑

第8章 全球寵物藥品市場：依通路分類

  • 動物診所
  • 藥局
  • 線上零售
  • 寵物專賣店
  • 其他分銷管道

第9章 全球寵物藥品市場：依應用分類

  • 感染疾病
  • 慢性病
  • 寄生蟲感染疾病
  • 疼痛管理
  • 疫苗接種
  • 其他用途

第10章：全球寵物藥品市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • Zoetis Inc.
  • Elanco Animal Health Incorporated
  • Merck Animal Health
  • Boehringer Ingelheim Animal Health
  • Ceva Sante Animale
  • Virbac SA
  • Dechra Pharmaceuticals PLC
  • Vetoquinol SA
  • IDEPet Pharmaceuticals Laboratories, Inc.
  • Heska Corporation
  • Phibro Animal Health Corporation
  • Neogen Corporation
  • Bayer AG（Animal Health division）
  • Sanofi（Animal Health legacy）
  • Zydus Animal Health
  • Intas Pharmaceuticals
Product Code: SMRC35097

According to Stratistics MRC, the Global Pet Pharmaceuticals Market is accounted for $18 billion in 2026 and is expected to reach $35 billion by 2034 growing at a CAGR of 8.5% during the forecast period. Pet Pharmaceuticals refer to medicinal products used to prevent, diagnose, and treat diseases in companion animals. These include vaccines, anti-infectives, parasiticides, pain management drugs, and specialty therapeutics. The market is driven by rising pet ownership, increased spending on pet healthcare, and advancements in veterinary medicine. Regulatory oversight ensures safety and efficacy. Growing awareness of preventive care and chronic disease management is expanding demand for pharmaceutical solutions, making this segment a critical part of the broader animal healthcare industry.

Market Dynamics:

Driver:

Rising pet ownership and healthcare spending

Families worldwide are treating pets as integral members of households, leading to higher demand for veterinary care. Growing awareness of preventive healthcare and wellness is reinforcing pharmaceutical adoption. Governments and NGOs are promoting vaccination and parasite control programs, strengthening market visibility. Rising disposable incomes are enabling owners to invest in premium healthcare solutions for pets. Pharmaceutical companies are expanding product ranges to cater to diverse pet needs, from companion animals to livestock.

Restraint:

Regulatory approval complexities

Pet pharmaceuticals must undergo rigorous testing and certification to ensure safety and efficacy. This processes increase costs and delay product launches, particularly for smaller firms. Variations in regulatory frameworks across regions add complexity for global manufacturers. Compliance requirements often limit innovation and slow down commercialization. Companies face challenges in balancing speed-to-market with strict approval standards. As oversight intensifies, regulatory complexities will continue to restrict the pace of growth in the pet pharmaceuticals sector.

Opportunity:

Expansion in preventive healthcare solutions

Preventive products such as vaccines, supplements, and parasiticides are gaining traction among pet owners. Rising awareness of long-term health benefits is driving demand for preventive care. Governments are supporting preventive programs to reduce disease incidence in companion and farm animals. Pharmaceutical companies are investing in R&D to develop advanced preventive solutions. Partnerships with veterinary clinics and pet care providers are reinforcing adoption.

Threat:

Stringent regulatory compliance requirements

Governments enforce strict standards for manufacturing, labeling, and distribution of pet pharmaceuticals. Non-compliance can lead to recalls, fines, and reputational damage. Smaller firms often struggle to meet these requirements compared to established corporations. Regulatory changes across regions add uncertainty to long-term planning. Compliance costs increase operational burdens and reduce profitability. Without robust adherence to standards, companies risk losing market share and credibility in the pet healthcare industry.

Covid-19 Impact:

The Covid-19 pandemic had mixed effects on the pet pharmaceuticals market. Supply chain disruptions initially slowed production and distribution of veterinary medicines. However, rising pet adoption during lockdowns boosted demand for healthcare products. Owners sought preventive and wellness solutions to ensure pet safety during the pandemic. Telemedicine and online retail platforms became vital channels for pharmaceutical distribution. Governments emphasized animal health as part of broader public health initiatives. Overall, Covid-19 reshaped consumer behavior while reinforcing the importance of resilience and adaptability in the pet healthcare sector.

The parasiticides segment is expected to be the largest during the forecast period

The parasiticides segment is expected to account for the largest market share during the forecast period as these products are widely used for preventive care. Parasiticides protect pets against fleas, ticks, and worms, ensuring long-term health and safety. Continuous innovation in formulations is improving efficacy and convenience. Governments are supporting parasite control programs through awareness campaigns and subsidies. Veterinary clinics are increasingly recommending parasiticides as part of routine care. Retailers are expanding assortments to meet consistent demand for these products.

The online retail segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the online retail segment is predicted to witness the highest growth rate due to rising demand for convenience and accessibility. Pet owners are increasingly purchasing pharmaceuticals through e-commerce platforms. Online channels offer wider product variety, competitive pricing, and doorstep delivery. Governments are supporting digital retail expansion through infrastructure and policy frameworks. Partnerships between pharmaceutical companies and online platforms are driving visibility and sales. Digital marketing campaigns are reinforcing consumer engagement and brand loyalty.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to strong consumer demand and advanced veterinary infrastructure. The U.S. leads in pet healthcare innovation, with a wide range of pharmaceutical products available. Government-backed animal health programs ensure steady demand for preventive and therapeutic solutions. Established brands and retailers are driving commercialization of pet pharmaceuticals. Rising demand for premium and organic variants is reshaping product portfolios. Investor confidence in sustainability-focused projects is further strengthening adoption.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by rapid urbanization and rising disposable incomes. Countries such as China, India, and Japan are witnessing strong demand for pet healthcare products. Government-backed initiatives promoting animal health and welfare are boosting adoption. Local startups are entering the market with cost-effective and innovative solutions tailored to regional needs. Expansion of e-commerce and modern veterinary services is further supporting growth. Rising awareness of preventive healthcare is reshaping consumer preferences in emerging economies.

Key players in the market

Some of the key players in Pet Pharmaceuticals Market include Zoetis Inc., Elanco Animal Health Incorporated, Merck Animal Health, Boehringer Ingelheim Animal Health, Ceva Sante Animale, Virbac S.A., Dechra Pharmaceuticals PLC, Vetoquinol S.A., IDEPet Pharmaceuticals Laboratories, Inc., Heska Corporation, Phibro Animal Health Corporation, Neogen Corporation, Bayer AG (Animal Health division), Sanofi (Animal Health legacy), Zydus Animal Health and Intas Pharmaceuticals.

Key Developments:

In February 2025, Elanco announced a major agreement with South Dakota-based Medgene to commercialize a highly pathogenic avian influenza (HPAI) vaccine for use in dairy cattle, leveraging Medgene's innovative vaccine platform technology. This partnership strengthens Elanco's diverse dairy portfolio and advances its "One Health" platform, addressing a critical need as the HPAI virus had spread to nearly 1,000 dairy herds across the U.S.

In December 2024, Zoetis announced the global launch of its new point-of-care hematology analyzer, which uses AI to provide accurate complete blood count (CBC) analysis in minutes. First installations were planned for early 2025 in the USA, Canada, UK, and other key markets.

Product Types Covered:

  • Anti-Infectives
  • Anti-Inflammatory Drugs
  • Parasiticides
  • Vaccines
  • Pain Management Drugs
  • Other Product Types

Animal Types Covered:

  • Dogs
  • Cats
  • Horses
  • Birds
  • Other Animal Types

Route of Administration Covered:

  • Oral
  • Injectable
  • Topical
  • Other Routes of Administration

Distribution Channels Covered:

  • Veterinary Clinics
  • Pharmacies
  • Online Retail
  • Pet Specialty Stores
  • Other Distribution Channels

Applications Covered:

  • Infectious Diseases
  • Chronic Conditions
  • Parasitic Infections
  • Pain Management
  • Immunization
  • Other Applications

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Pet Pharmaceuticals Market, By Product Type

  • 5.1 Anti-Infectives
  • 5.2 Anti-Inflammatory Drugs
  • 5.3 Parasiticides
  • 5.4 Vaccines
  • 5.5 Pain Management Drugs
  • 5.6 Other Product Types

6 Global Pet Pharmaceuticals Market, By Animal Type

  • 6.1 Dogs
  • 6.2 Cats
  • 6.3 Horses
  • 6.4 Birds
  • 6.5 Other Animal Types

7 Global Pet Pharmaceuticals Market, By Route of Administration

  • 7.1 Oral
  • 7.2 Injectable
  • 7.3 Topical
  • 7.4 Other Routes of Administration

8 Global Pet Pharmaceuticals Market, By Distribution Channel

  • 8.1 Veterinary Clinics
  • 8.2 Pharmacies
  • 8.3 Online Retail
  • 8.4 Pet Specialty Stores
  • 8.5 Other Distribution Channels

9 Global Pet Pharmaceuticals Market, By Application

  • 9.1 Infectious Diseases
  • 9.2 Chronic Conditions
  • 9.3 Parasitic Infections
  • 9.4 Pain Management
  • 9.5 Immunization
  • 9.6 Other Applications

10 Global Pet Pharmaceuticals Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Zoetis Inc.
  • 13.2 Elanco Animal Health Incorporated
  • 13.3 Merck Animal Health
  • 13.4 Boehringer Ingelheim Animal Health
  • 13.5 Ceva Sante Animale
  • 13.6 Virbac S.A.
  • 13.7 Dechra Pharmaceuticals PLC
  • 13.8 Vetoquinol S.A.
  • 13.9 IDEPet Pharmaceuticals Laboratories, Inc.
  • 13.10 Heska Corporation
  • 13.11 Phibro Animal Health Corporation
  • 13.12 Neogen Corporation
  • 13.13 Bayer AG (Animal Health division)
  • 13.14 Sanofi (Animal Health legacy)
  • 13.15 Zydus Animal Health
  • 13.16 Intas Pharmaceuticals

List of Tables

  • Table 1 Global Pet Pharmaceuticals Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Pet Pharmaceuticals Market, By Product Type (2023-2034) ($MN)
  • Table 3 Global Pet Pharmaceuticals Market, By Anti-Infectives (2023-2034) ($MN)
  • Table 4 Global Pet Pharmaceuticals Market, By Anti-Inflammatory Drugs (2023-2034) ($MN)
  • Table 5 Global Pet Pharmaceuticals Market, By Parasiticides (2023-2034) ($MN)
  • Table 6 Global Pet Pharmaceuticals Market, By Vaccines (2023-2034) ($MN)
  • Table 7 Global Pet Pharmaceuticals Market, By Pain Management Drugs (2023-2034) ($MN)
  • Table 8 Global Pet Pharmaceuticals Market, By Other Product Types (2023-2034) ($MN)
  • Table 9 Global Pet Pharmaceuticals Market, By Animal Type (2023-2034) ($MN)
  • Table 10 Global Pet Pharmaceuticals Market, By Dogs (2023-2034) ($MN)
  • Table 11 Global Pet Pharmaceuticals Market, By Cats (2023-2034) ($MN)
  • Table 12 Global Pet Pharmaceuticals Market, By Horses (2023-2034) ($MN)
  • Table 13 Global Pet Pharmaceuticals Market, By Birds (2023-2034) ($MN)
  • Table 14 Global Pet Pharmaceuticals Market, By Other Animal Types (2023-2034) ($MN)
  • Table 15 Global Pet Pharmaceuticals Market, By Route of Administration (2023-2034) ($MN)
  • Table 16 Global Pet Pharmaceuticals Market, By Oral (2023-2034) ($MN)
  • Table 17 Global Pet Pharmaceuticals Market, By Injectable (2023-2034) ($MN)
  • Table 18 Global Pet Pharmaceuticals Market, By Topical (2023-2034) ($MN)
  • Table 19 Global Pet Pharmaceuticals Market, By Other Routes of Administration (2023-2034) ($MN)
  • Table 20 Global Pet Pharmaceuticals Market, By Distribution Channel (2023-2034) ($MN)
  • Table 21 Global Pet Pharmaceuticals Market, By Veterinary Clinics (2023-2034) ($MN)
  • Table 22 Global Pet Pharmaceuticals Market, By Pharmacies (2023-2034) ($MN)
  • Table 23 Global Pet Pharmaceuticals Market, By Online Retail (2023-2034) ($MN)
  • Table 24 Global Pet Pharmaceuticals Market, By Pet Specialty Stores (2023-2034) ($MN)
  • Table 25 Global Pet Pharmaceuticals Market, By Other Distribution Channels (2023-2034) ($MN)
  • Table 26 Global Pet Pharmaceuticals Market, By Application (2023-2034) ($MN)
  • Table 27 Global Pet Pharmaceuticals Market, By Infectious Diseases (2023-2034) ($MN)
  • Table 28 Global Pet Pharmaceuticals Market, By Chronic Conditions (2023-2034) ($MN)
  • Table 29 Global Pet Pharmaceuticals Market, By Parasitic Infections (2023-2034) ($MN)
  • Table 30 Global Pet Pharmaceuticals Market, By Pain Management (2023-2034) ($MN)
  • Table 31 Global Pet Pharmaceuticals Market, By Immunization (2023-2034) ($MN)
  • Table 32 Global Pet Pharmaceuticals Market, By Other Applications (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.